Anti-Angiogenesis Drug Discovery and Development

Volume: 4

Anti-Angiogenesis Drugs: Hopes and Disappointments in Certain Cancers

Author(s): Georgios M. Iatrakis

Pp: 97-107 (11)

DOI: 10.2174/9781681083971119040006

* (Excluding Mailing and Handling)


In cancer, neovascularization seems necessary for tumor progression and metastasis. The hypothesis that cancer progression is angiogenesis-dependent has repeatedly been confirmed by experimental inhibition of tumor growth with angiogenesis inhibitors. Receptors for VEGF (VEGFRs) are expressed on tumor endothelium and tumor cells and, as expected, VEGF-A overexpression is associated with poor prognosis (reduced survival). There are both positive and negative angiogenesis regulators and, as such, two strategies for inhibiting pathologic angiogenesis can be adopted: the inhibition of positively-acting agents (e.g., VEGFR inhibitors) and the administration of negatively-acting agents (e.g., angiostatin (from the Greek words "angio" and "stasis" meaning stopping)).

Keywords: Angiogenesis, Anti-angiogenesis drugs, Cancer, Growth factors, Negative angiogenesis regulators, Positive angiogenesis regulators.

Related Journals
Related Books
© 2024 Bentham Science Publishers | Privacy Policy